Project Grant R01CA299039
Award Date
4/3/25
Completion Date
3/31/30
Dollars Obligated
$593K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a $248,509 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant, titled "Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS", aims to advance the understanding of the pathophysiology of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), two...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,549.00 to Emory University to conduct research on targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The key objectives are to:
Comprehensively characterize and genetically perturb cross-species molecular features of MYC-hyperactivated human and murine osteosarcoma tumors to identify intrinsic and extrinsic signatures and cell-cell...
This $253,273 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports the Dana-Farber Cancer Institute's research to validate circulating tumor DNA (ctDNA) as a prognostic biomarker for adolescents and young adults (AYAs) with sarcomas.
The key objectives are to: 1) determine ctDNA-based prognostic thresholds for risk of relapse in fusion-negative sarcomas at baseline; 2) determine ctDNA-based prognostic thresholds for risk of relapse in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $1,243,002 will fund research aimed at improving survival rates for children with diffuse midline gliomas (DMG), a type of malignant brain tumor. The grant recipient, Dana-Farber Cancer Institute, will collaborate with researchers at the University of California, San Francisco to test the hypothesis that combining radiation therapy with drugs targeting DNA replication...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979.00 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding and disrupting tumor metabolism and enhancing anti-tumor immunity in diffuse midline gliomas (DMGs), a type of aggressive pediatric brain cancer. The key goals are to: 1) Delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1...
This $931,841 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund the development of next-generation immunotherapies for pediatric cancers at Stanford University. The project aims to create safer and more effective targeted treatments that can improve cure rates and reduce toxicities compared to current standard cytotoxic regimens. Key focus areas include overcoming the suppressive tumor microenvironment in pediatric solid tumors,...
This $514,405 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research by Sanford Research to investigate the role of cancer-dependent skeletal genes and pathways in the development and progression of osteosarcoma, a fatal bone tumor that primarily affects children. The research aims to elucidate the molecular mechanisms underlying the link between cancer-dependent skeletal pathways and osteosarcoma growth, with the goal of...
This $482,175 project grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of California, San Francisco (UCSF) to target the mTORC1 translational control pathway in fusion-positive rhabdomyosarcoma, a form of childhood cancer. The key objectives are to define the molecular basis for the cancer's "addiction" to cap-dependent translation driven by the PAX3-FOXO1 oncogenic fusion protein, and to identify optimal...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $364,848 to the Dana-Farber Cancer Institute to investigate IGF2BP1 as a novel therapeutic target for Ewing's sarcoma, an aggressive pediatric bone cancer. The primary research activities involve using CRISPR-Cas9 gene editing to validate IGF2BP1 as an Ewing's sarcoma dependency, determining the molecular mechanisms underlying the IGF2BP1 dependency, and biochemically characterizing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $218,068 to St. Jude Children's Research Hospital Inc. to study the impact of bidirectional signaling between megakaryocytes (cells that produce platelets) and osteosarcoma cells on metastasis. The research aims to understand how interactions between osteosarcoma and megakaryocytes within the bone microenvironment influence tumor progression and metastasis. Specific objectives...